DR NEERGAARDS VEJ 5F, HOERSHOLM, G7
Announces Amendment to Articles of Association and Sale of American Depositary Shares
Reports Unaudited Condensed Consolidated Interim Financial Statements for the Period Ended June 30, 2026
Announces Business Update and Second Quarter 2026 Financial Results
Expands and Refocuses R&D Pipeline with EVX-05, an AI-Designed Off-the-Shelf Brain Cancer Vaccine Program
To announce business update and second quarter 2026 financial results on August 20, 2026
To Present Three-Year Clinical Efficacy Data for Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2026
Presents New Preclinical Data for Cytomegalovirus Vaccine Program EVX-V1
To present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities of Certain Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities of Certain Foreign Private Issuers
No filings found
Initial Statement of Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
Correspondence
Submission Upload